DCGI gives emergency approval of DRDO developed 2-DG anti-COVID oral drug

DCGI has given emergency approval to DRDO-developed anti-Covid oral drug named 2-DG. The oral drug has been developed in association with the Institute of Nuclear Medicine and Allied Sciences in partnership with Dr. Reddy’s Laboratories, Hyderabad. The Phase III clinical trial results of the 2-DG have shown that this molecule enables quick recovery of hospitalized… Continue reading DCGI gives emergency approval of DRDO developed 2-DG anti-COVID oral drug